Reduction‐Sensitive Fluorinated‐Pt(IV) Universal Transfection Nanoplatform Facilitating CT45‐Targeted CRISPR/dCas9 Activation for Synergistic and Individualized Treatment of Ovarian Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reduction‐Sensitive Fluorinated‐Pt(IV) Universal Transfection Nanoplatform Facilitating CT45‐Targeted CRISPR/dCas9 Activation for Synergistic and Individualized Treatment of Ovarian Cancer

Published:2021-09-12 Issue:41 Volume:17 Page:2102494
ISSN:1613-6810
Container-title:Small
language:en
Short-container-title:Small

Author:

Lu Hongtong¹²,Zhang Qingfei¹²,He Shasha¹,Liu Sha¹²,Xie Zhigang¹²,Li Xiaoyuan¹³,Huang Yubin¹³^ORCID

Affiliation:

1. State Key Laboratory of Polymer Physics and Chemistry Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun 130022 P. R. China

2. University of Science and Technology of China Hefei 230026 P. R. China

3. Faculty of Chemistry Northeast Normal University Changchun 130024 P. R. China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/smll.202102494

Reference57 articles.

1. What’s new in clinical CRISPR?

2. Therapeutic genome editing: prospects and challenges

3. Genome engineering using the CRISPR-Cas9 system

4. Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity

5. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs;Coordination Chemistry Reviews;2024-06

2. Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer;Molecular Therapy: Oncology;2024-03

3. Iron‐Confined CRISPR/Cas9‐Ribonucleoprotein Delivery System for Redox‐Responsive Gene Editing;Small;2024-02-25

4. Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment;MedComm – Biomaterials and Applications;2024-01-14

5. CRISPR/Cas gene editing and delivery systems for cancer therapy;WIREs Nanomedicine and Nanobiotechnology;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3